

Genitourinary Cancers

Pfizer is a proven leader in developing innovative medicines for genitourinary (GU) cancers with a longstanding commitment to transforming care and outcomes for people with these cancers.

Due to the complexity of GU cancers, the increasing number of people diagnosed with these diseases and high rates of recurrence and progression, there continues to be a high unmet need. Across our Pfizer Oncology portfolio, including GU, we are *actively pursuing our goal to move rapidly into early stage disease* to achieve significant advances for people living with GU cancers. We are also exploring new modalities in preclinical research with the goal of bringing transformational medicines that mean even more breakthroughs and meaningful advancements for people living with GU cancers in the future.

Click below for more information:

—
Legacy and Innovation:
Pfizer Oncology's Commitment
to GU Cancers

UPDATED: May 2021

